Equities analysts predict that ArQule, Inc. (NASDAQ:ARQL) will announce earnings per share of ($0.06) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for ArQule’s earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.10). ArQule posted earnings per share of ($0.09) in the same quarter last year, which indicates a positive year-over-year growth rate of 33.3%. The business is expected to announce its next earnings results on Thursday, November 8th.

According to Zacks, analysts expect that ArQule will report full year earnings of ($0.12) per share for the current fiscal year, with EPS estimates ranging from ($0.16) to ($0.05). For the next financial year, analysts anticipate that the company will post earnings of ($0.28) per share, with EPS estimates ranging from ($0.41) to ($0.10). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for ArQule.

ArQule (NASDAQ:ARQL) last issued its earnings results on Wednesday, August 1st. The biotechnology company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.03 by $0.02. The firm had revenue of $13.71 million during the quarter, compared to analyst estimates of $7.70 million. During the same quarter in the previous year, the business posted ($0.12) EPS.

ARQL has been the topic of several recent research reports. ValuEngine raised ArQule from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 26th. Zacks Investment Research downgraded ArQule from a “buy” rating to a “hold” rating in a report on Tuesday, June 5th. BidaskClub raised ArQule from a “buy” rating to a “strong-buy” rating in a report on Friday, May 25th. Finally, Needham & Company LLC raised their price target on ArQule from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, June 18th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. ArQule presently has an average rating of “Buy” and an average target price of $6.65.

Shares of NASDAQ ARQL traded down $0.02 during mid-day trading on Friday, hitting $5.85. The company had a trading volume of 723,967 shares, compared to its average volume of 1,426,343. The company has a market cap of $657.26 million, a price-to-earnings ratio of -15.00 and a beta of 0.85. ArQule has a 12 month low of $0.97 and a 12 month high of $7.21. The company has a current ratio of 5.99, a quick ratio of 5.99 and a debt-to-equity ratio of 0.54.

In related news, insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the firm’s stock in a transaction that occurred on Wednesday, May 30th. The stock was sold at an average price of $5.00, for a total value of $5,179,695.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 7.90% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in ARQL. Jane Street Group LLC bought a new stake in ArQule during the 1st quarter valued at $100,000. CAPROCK Group Inc. bought a new stake in ArQule during the 2nd quarter valued at $109,000. Zebra Capital Management LLC bought a new stake in ArQule during the 2nd quarter valued at $115,000. Millennium Management LLC bought a new stake in ArQule during the 4th quarter valued at $165,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in ArQule during the 2nd quarter valued at $169,000. 67.99% of the stock is currently owned by institutional investors and hedge funds.

ArQule Company Profile

ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. It offers Derazantinib (ARQ 087), a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family that is in a registration trial in intrahepatic cholangiocarcinoma with FGFR2 fusions.

Recommended Story: Short Selling – Explanation For Shorting Stocks

Get a free copy of the Zacks research report on ArQule (ARQL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ArQule (NASDAQ:ARQL)

Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.